|
1
|
Brown JS, Amend SR, Austin RH, Gatenby RA, Hammarlund EU and Pienta KJ: Updating the definition of cancer. Mol Cancer Res. 21:1142–1147. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Szyfter K: Genetics and molecular biology of head and neck cancer. Biomolecules. 11:12932021. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Jerjes WK, Upile T, Wong BJ, Betz CS, Sterenborg HJ, Witjes MJ, Berg K, van Veen R, Biel MA, El-Naggar AK, et al: The future of medical diagnostics: review paper. Head Neck Oncol. 3:382011. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ruffin AT, Li H, Vujanovic L, Zandberg DP, Ferris RL and Bruno TC: Improving head and neck cancer therapies by immunomodulation of the tumour microenvironment. Nat Rev Cancer. 23:173–188. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Langer CJ: Exploring biomarkers in head and neck cancer. Cancer. 118:3882–3892. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Head and Neck Cancer Study Group (HNCSG), . Monden N, Asakage T, Kiyota N, Homma A, Matsuura K, Hanai N, Kodaira T, Zenda S, Fujii H, et al: A review of head and neck cancer staging system in the TNM classification of malignant tumors (eighth edition). Jpn J Clin Oncol. 49:589–595. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Field JK, Zoumpourlis V, Spandidos DA and Jones AS: p53 expression and mutations in squamous cell carcinoma of the head and neck: Expression correlates with the patients' use of tobacco and alcohol. Cancer Detect Prev. 18:197–208. 1994.PubMed/NCBI
|
|
8
|
Barsouk A, Aluru JS, Rawla P, Saginala K and Barsouk A: Epidemiology, risk factors, and prevention of head and neck squamous cell carcinoma. Med Sci (Basel). 11:422023.PubMed/NCBI
|
|
9
|
Watling DL, Gown AM and Coltrera MD: Overexpression of p53 in head and neck cancer. Head Neck. 14:437–444. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Field JK, Spandidos DA, Malliri A, Gosney JR, Yiagnisis M and Stell PM: Elevated P53 expression correlates with a history of heavy smoking in squamous cell carcinoma of the head and neck. Br J Cancer. 64:573–577. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Svider PF, Blasco MA, Raza SN, Shkoukani M, Sukari A, Yoo GH, Folbe AJ, Lin HS and Fribley AM: Head and neck cancer. Otolaryngol Head Neck Surg. 156:10–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Field JK, Spandidos DA and Stell PM: Overexpression of p53 gene in head-and-neck cancer, linked with heavy smoking and drinking. Lancet. 339:502–503. 1992. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steuer CE, El-Deiry M, Parks JR, Higgins KA and Saba NF: An update on larynx cancer. CA Cancer J Clin. 67:31–50. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Anderson G, Ebadi M, Vo K, Novak J, Govindarajan A and Amini A: An updated review on head and neck cancer treatment with radiation therapy. Cancers (Basel). 13:49122021. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jiang Z, Wu C, Zhao Y, Zhan Q, Wang K and Li Y: Global research trends in immunotherapy for head and neck neoplasms: A scientometric study. Heliyon. 9:e153092023. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pereira D, Martins D and Mendes F: Immunotherapy in head and neck cancer when, how, and why? Biomedicines. 10:21512022. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kleszcz R: Advantages of the combinatorial molecular targeted therapy of head and neck cancer-A step before anakoinosis-based personalized treatment. Cancers (Basel). 15:42472023. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hijazi MA, Gessner A and El-Najjar N: Repurposing of chronically used drugs in cancer therapy: A chance to grasp. Cancers (Basel). 15:31992023. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xia Y, Sun M, Huang H and Jin WL: Drug repurposing for cancer therapy. Signal Transduct Target Ther. 9:922024. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Johnson FM, Janku F, Gouda MA, Tran HT, Kawedia JD, Schmitz D, Streefkerk H, Lee JJ, Andersen CR, Deng D, et al: Inhibition of the phosphatidylinositol-3 kinase pathway using bimiralisib in loss-of-function NOTCH1-Mutant head and neck cancer. Oncologist. 27:1004–e1926. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li C, Geng H, Ji L, Ma X, Yin Q and Xiong H: ESM-1: A novel tumor biomaker and its research advances. Anticancer Agents Med Chem. 19:1687–1694. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wurzba S, Salo TA and Coletta RD: Editorial: Prognostic biomarkers for oral cancer. Front Oral Health. 3:9943872022. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang HC, Yeh TJ, Chan LP, Hsu CM and Cho SF: Exploration of feasible immune biomarkers for immune checkpoint inhibitors in head and neck squamous cell carcinoma treatment in real World clinical practice. Int J Mol Sci. 21:76212020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
El-Naggar A: Pathobiology of head and neck squamous tumorigenesis. Curr Cancer Drug Targets. 7:606–612. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes. Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Curtius K, Wright NA and Graham TA: Evolution of premalignant disease. Cold Spring Harb Perspect Med. 7:a0265422017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, Meyerson M, Gabriel SB, Lander ES and Getz G: Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 505:495–501. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Leshchiner I, Mroz EA, Cha J, Rosebrock D, Spiro O, Bonilla-Velez J, Faquin WC, Lefranc-Torres A, Lin DT, Michaud WA, et al: Inferring early genetic progression in cancers with unobtainable premalignant disease. Nat Cancer. 4:550–563. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE and Grandis JR: Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 6:922020. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Mbeunkui F and Johann DJ Jr: Cancer and the tumor microenvironment: A review of an essential relationship. Cancer Chemother Pharmacol. 63:571–582. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME, Wicha MS and Nör JE: Endothelial cell-initiated signaling promotes the survival and self-renewal of cancer stem cells. Cancer Res. 70:9969–9978. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Vashisht S, Mishra H, Mishra PK, Ekielski A and Talegaonkar S: Structure, genome, infection cycle and clinical manifestations associated with human papillomavirus. Curr Pharm Biotechnol. 20:1260–1280. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mehanna H, Taberna M, von Buchwald C, Tous S, Brooks J, Mena M, Morey F, Grønhøj C, Rasmussen JH, Garset-Zamani M, et al: Prognostic implications of p16 and HPV discordance in oropharyngeal cancer (HNCIG-EPIC-OPC): A multicentre, multinational, individual patient data analysis. Lancet Oncol. 24:239–251. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Roman BR and Aragones A: Epidemiology and incidence of HPV-related cancers of the head and neck. J Surg Oncol. 124:920–922. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Dokianakis DN, Papaefthimiou M, Tsiveleka A and Spandidos DA: High prevalence of HPV18 in correlation with ras gene mutations and clinicopathological parameters in cervical cancer studied from stained cytological smears. Oncol Rep. 6:1327–1331. 1999.PubMed/NCBI
|
|
36
|
Galati L, Chiocca S, Duca D, Tagliabue M, Simoens C, Gheit T, Arbyn M and Tommasino M: HPV and head and neck cancers: Towards early diagnosis and prevention. Tumour Virus Res. 14:2002452022. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Lechner M, Liu J, Masterson L and Fenton TR: HPV-associated oropharyngeal cancer: Epidemiology, molecular biology and clinical management. Nat Rev Clin Oncol. 19:306–327. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
El-Naggar AK and Westra WH: p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency. Head Neck. 34:459–461. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Ramesh PS, Bovilla VR, Swamy VH, Manoli NN, Dasegowda KB, Siddegowda SM, Chandrashekarappa S, Somasundara VM, Kabekkodu SP, Rajesh R, et al: Human papillomavirus-driven repression of NRF2 signalling confers chemo-radio sensitivity and predicts prognosis in head and neck squamous cell carcinoma. Free Radic Biol Med. 205:234–243. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Holzinger D, Flechtenmacher C, Henfling N, Kaden I, Grabe N, Lahrmann B, Schmitt M, Hess J, Pawlita M and Bosch FX: Identification of oropharyngeal squamous cell carcinomas with active HPV16 involvement by immunohistochemical analysis of the retinoblastoma protein pathway. Int J Cancer. 133:1389–1399. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Lechner M, Chakravarthy AR, Walter V, Masterson L, Feber A, Jay A, Weinberger PM, McIndoe RA, Forde CT, Chester K, et al: Frequent HPV-independent p16/INK4A overexpression in head and neck cancer. Oral Oncol. 83:32–37. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Kuhn JP, Schmid W, Korner S, Bochen F, Wemmert S, Rimbach H, Smola S, Radosa JC, Wagner M, Morris LGT, et al: HPV status as prognostic biomarker in head and neck cancer-which method fits the best for outcome prediction? Cancers (Basel). 13:47302021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Sánchez Barrueco A, González Galán F, Villacampa Aubá JM, Díaz Tapia G, Fernández Hernández S, Martín-Arriscado Arroba C, Cenjor Español C and Almodóvar Álvarez C: p16 influence on laryngeal squamous cell carcinoma relapse and survival. Otolaryngol Head Neck Surg. 160:1042–1047. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Chung CH, Zhang Q, Kong CS, Harris J, Fertig EJ, Harari PM, Wang D, Redmond KP, Shenouda G, Trotti A, et al: p16 protein expression and human papillomavirus status as prognostic biomarkers of nonoropharyngeal head and neck squamous cell carcinoma. J Clin Oncol. 32:3930–3938. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kori M and Arga KY: HPV16 status predicts potential protein biomarkers and therapeutics in head and neck squamous cell carcinoma. Virology. 582:90–99. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Wise-Draper TM, Bahig H, Tonneau M, Karivedu V and Burtness B: Current therapy for metastatic head and neck cancer: Evidence, opportunities, and challenges. Am Soc Clin Oncol Educ Book. 42:1–14. 2022.PubMed/NCBI
|
|
47
|
Liloglou T, Scholes AG, Spandidos DA, Vaughan ED, Jones AS and Field JK: p53 mutations in squamous cell carcinoma of the head and neck predominate in a subgroup of former and present smokers with a low frequency of genetic instability. Cancer Res. 57:4070–4074. 1997.PubMed/NCBI
|
|
48
|
Carpov D, Buiga R and Nagy VM: DNA damage response and potential biomarkers of radiosensitivity in head and neck cancers: clinical implications. Rom J Morphol Embryol. 64:5–13. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Wang J, Hu Y, Escamilla-Rivera V, Gonzalez CL, Tang L, Wang B, El-Naggar AK, Myers JN and Caulin C: Epithelial mutant p53 promotes resistance to Anti-PD-1-Mediated oral cancer immunoprevention in carcinogen-induced mouse models. Cancers (Basel). 13:14712021. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Solomon B, Young RJ and Rischin D: Head and neck squamous cell carcinoma: Genomics and emerging biomarkers for immunomodulatory cancer treatments. Semin Cancer Biol. 52((Pt 2)): 228–240. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Amenabar JM, Da Silva BM and Punyadeera C: Salivary protein biomarkers for head and neck cancer. Expert Rev Mol Diagn. 20:305–313. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Kampel L, Feldstein S, Tsuriel S, Hannes V, Carmel Neiderman NN, Horowitz G, Warshavsky A, Leider-Trejo L, Hershkovitz D and Muhanna N: Mutated TP53 in circulating tumor DNA as a risk level biomarker in head and neck squamous cell carcinoma patients. Biomolecules. 13:14182023. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yu R, Sun T, Zhang X, Li Z, Xu Y, Liu K, Shi Y, Wu X, Shao Y and Kong L: TP53 Co-Mutational Features and NGS-Calibrated immunohistochemistry threshold in gastric cancer. Onco Targets Ther. 14:4967–4978. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Peltonen JK, Helppi HM, Paakko P, Turpeenniemi-Hujanen T and Vahakangas KH: p53 in head and neck cancer: functional consequences and environmental implications of TP53 mutations. Head Neck Oncol. 2:362010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Field J, Malliri A, Butt S, Gosney J, Phillips D, Spandidos D and Jones A: P53 expression in end-stage squamous-cell carcinoma of the head and neck prior to chemotherapy treatment-expression correlates with a very poor clinical outcome. Int J Oncol. 3:431–435. 1993.PubMed/NCBI
|
|
56
|
Field J, Malliri A, Jones A and Spandidos D: Mutations in the p53 gene at codon 249 are rare in squamous-cell carcinoma of the head and neck. Int J Oncol. 1:253–256. 1992.PubMed/NCBI
|
|
57
|
Jagadeeshan S, Novoplansky OZ, Cohen O, Kurth I, Hess J, Rosenberg AJ, Grandis JR and Elkabets M: New insights into RAS in head and neck cancer. Biochim Biophys Acta Rev Cancer. 1878:1889632023. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Novoplansky O, Jagadeeshan S, Regev O, Menashe I and Elkabets M: Worldwide prevalence and clinical characteristics of RAS mutations in head and neck cancer: A systematic review and meta-analysis. Front Oncol. 12:8389112022. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Weidhaas JB, Harris J, Schaue D, Chen AM, Chin R, Axelrod R, El-Naggar AK, Singh AK, Galloway TJ, Raben D, et al: The KRAS-Variant and cetuximab response in head and neck squamous cell cancer: A secondary analysis of a Randomized clinical trial. JAMA Oncol. 3:483–491. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Rampias T, Giagini A, Siolos S, Matsuzaki H, Sasaki C, Scorilas A and Psyrri A: RAS/PI3K crosstalk and cetuximab resistance in head and neck squamous cell carcinoma. Clin Cancer Res. 20:2933–2946. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Wang J, Al-Majid D, Brenner JC and Smith JD: Mutant HRas signaling and rationale for use of farnesyltransferase inhibitors in head and neck squamous cell carcinoma. Target Oncol. 18:643–655. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Coleman N, Marcelo KL, Hopkins JF, Khan NI, Du R, Hong L, Park E, Balsara B, Leoni M, Pickering C, et al: HRAS mutations define a distinct subgroup in head and neck squamous cell carcinoma. JCO Precis Oncol. 7:e22002112023. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Sasaki E, Masago K, Fujita S, Hanai N and Yatabe Y: Frequent KRAS and HRAS mutations in squamous cell papillomas of the head and neck. J Pathol Clin Res. 6:154–159. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Papanikolaou V, Chrysovergis A, Mastronikolis S, Tsiambas E, Ragos V, Peschos D, Spyropoulou D, Pantos P, Niotis A, Mastronikolis N and Kyrodimos E: Impact of K-Ras Over-expression in laryngeal squamous cell carcinoma. In Vivo. 35:1611–1615. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Wei F, Wu Y, Wang Z, Li Y, Wang J, Shao G, Yang Y and Shi B: Diagnostic significance of DNA methylation of PTEN and DAPK in thyroid tumors. Clin Endocrinol (Oxf). 93:187–195. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Qiu R, Wang W, Li J and Wang Y: Roles of PTEN inactivation and PD-1/PD-L1 activation in esophageal squamous cell carcinoma. Mol Biol Rep. 49:6633–6645. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Kim B, Kang SY, Kim D, Heo YJ and Kim KM: PTEN Protein Loss and Loss-of-Function mutations in gastric cancers: The relationship with microsatellite instability, EBV, HER2, and PD-L1 expression. Cancers (Basel). 12:17242020. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kerdjoudj M, De La Torre RA and Arnouk H: Characterization of DJ-1, PTEN, and p-Akt as prognostic biomarkers in the progression of oral squamous cell carcinoma. Cureus. 15:e344362023.PubMed/NCBI
|
|
69
|
Squarize CH, Castilho RM, Abrahao AC, Molinolo A, Lingen MW and Gutkind JS: PTEN deficiency contributes to the development and progression of head and neck cancer. Neoplasia. 15:461–471. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Blessy S, Sankar S and Girija AS: In silico analysis of key miRNAs and gene-network analysis of pten gene involved in head and neck cancer. J Surv Fish Sci. 10:198–204. 2023.
|
|
71
|
Saintigny P, Mitani Y, Pytynia KB, Ferrarotto R, Roberts DB, Weber RS, Kies MS, Maity SN, Lin SH and El-Naggar AK: Frequent PTEN loss and differential HER2/PI3K signaling pathway alterations in salivary duct carcinoma: Implications for targeted therapy. Cancer. 124:3693–3705. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Jasphin SS, Desai D, Pandit S, Gonsalves NM, Nayak PB and Iype A: Immunohistochemical expression of phosphatase and tensin homolog in histologic gradings of oral squamous cell carcinoma. Contemp Clin Dent. 7:524–528. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Vidotto T, Melo CM, Lautert-Dutra W, Chaves LP, Reis RB and Squire JA: Pan-cancer genomic analysis shows hemizygous PTEN loss tumors are associated with immune evasion and poor outcome. Sci Rep. 13:50492023. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Stelzer G, Rosen N, Plaschkes I, Zimmerman S, Twik M, Fishilevich S, Stein TI, Nudel R, Lieder I, Mazor Y, et al: The GeneCards Suite: From gene data mining to disease genome sequence analyses. Curr Protoc Bioinformatics. 54:1.30.1–1.30.33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Cuylen S, Blaukopf C, Politi AZ, Müller-Reichert T, Neumann B, Poser I, Ellenberg J, Hyman AA and Gerlich DW: Ki-67 acts as a biological surfactant to disperse mitotic chromosomes. Nature. 535:308–312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
MacCallum DE and Hall PA: The biochemical characterization of the DNA binding activity of pKi67. J Pathol. 191:286–298. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Urruticoechea A, Smith IE and Dowsett M: Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 23:7212–7220. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Kovesi G and Szende B: Changes in apoptosis and mitotic index, p53 and Ki67 expression in various types of oral leukoplakia. Oncology. 65:331–336. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Hellgren LS, Stenman A, Paulsson JO, Höög A, Larsson C, Zedenius J and Juhlin CC: Prognostic Utility of the Ki-67 labeling index in follicular thyroid tumors: A 20-Year experience from a tertiary thyroid center. Endocr Pathol. 33:231–242. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Ahmed MW, Kayani MA, Shabbir G, Ali SM, Shinwari WU and Mahjabeen I: Expression of PTEN and its correlation with proliferation marker Ki-67 in head and neck cancer. Int J Biol Markers. 31:e193–e203. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
He QY, Jin F, Li YY, Wu WL, Long JH, Luo XL, Gong XY, Chen XX, Bi T, Li ZL, et al: Prognostic significance of downregulated BMAL1 and upregulated Ki-67 proteins in nasopharyngeal carcinoma. Chronobiol Int. 35:348–357. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Huang SF, Cheng SD, Chuang WY, Chen IH, Liao CT, Wang HM and Hsieh LL: Cyclin D1 overexpression and poor clinical outcomes in Taiwanese oral cavity squamous cell carcinoma. World J Surg Oncol. 10:402012. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Rauf M, Azmat H, Shahab S, Ahmad A, Khadija S and Firidi J: Immunohistochemical expression of cyclind1 in conventional squamous cell carcinomaof oral cavity. J Ayub Med Coll Abbottabad. 35:11–16. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Gioacchini FM, Alicandri-Ciufelli M, Kaleci S, Magliulo G, Presutti L and Re M: The prognostic value of cyclin D1 expression in head and neck squamous cell carcinoma. Eur Arch Otorhinolaryngol. 273:801–809. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Yang K, Zhu G, Sun Y, Hu Y, Lv Y, Li Y, Pan J, Chen F, Zhou Y and Zhang J: Prognostic significance of cyclin D1 expression pattern in HPV-negative oral and oropharyngeal carcinoma: A deep-learning approach. J Oral Pathol Med. 52:919–929. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Wang CC, Lu DD, Shen MH, Chen RL, Zhang ZH and Lv JH: Clinical value of Cyclin D1 and P21 in the differential diagnosis of papillary thyroid carcinoma. Diagn Pathol. 18:1232023. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
John RR, Sam N and Chandrasekaran B: Prognostic significance of proliferative markers: Cyclin D1 and CENPF in oral squamous cell carcinoma patients-A cohort study. J Maxillofac Oral Surg. 22:734–740. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Li C, Li C, Zhi C, Liang W, Wang X, Chen X, Lv T, Shen Q, Song Y, Lin D and Liu H: Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients. J Transl Med. 17:3552019. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R and Siu LL: Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma. Ann Oncol. 30:57–67. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
William WN Jr, Zhang J, Zhao X, Parra ER, Uraoka N, Lin HY, Peng SA, El-Naggar AK, Rodriguez-Canales J, Song J, et al: Spatial PD-L1, immune-cell microenvironment, and genomic copy-number alteration patterns and drivers of invasive-disease transition in prospective oral precancer cohort. Cancer. 129:714–727. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Müller T, Braun M, Dietrich D, Aktekin S, Höft S, Kristiansen G, Göke F, Schröck A, Brägelmann J, Held SAE, et al: PD-L1: A novel prognostic biomarker in head and neck squamous cell carcinoma. Oncotarget. 8:52889–52900. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Malinowska K, Kowalski A, Merecz-Sadowska A, Paprocka-Zjawiona M, Sitarek P, Kowalczyk T and Zielińska-Bliźniewska H: PD-1 and PD-L1 expression levels as a potential biomarker of chronic Rhinosinusitis and head and neck cancers. J Clin Med. 12:20332023. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Jiang D, Song Q, Wang H, Huang J, Wang H, Hou J, Li X, Xu Y, Sujie A, Zeng H, et al: Independent prognostic role of PD-L1expression in patients with esophageal squamous cell carcinoma. Oncotarget. 8:8315–8329. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Shah PA, Huang C, Li Q, Kazi SA, Byers LA, Wang J, Johnson FM and Frederick MJ: NOTCH1 signaling in head and neck squamous cell carcinoma. Cells. 9:26772020. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Sadeghi ES, Nematpour FS, Mohtasham N and Mohajertehran F: The oncogenic role of NOTCH1 as biomarker in oral squamous cell carcinoma and oral lichen planus. Dent Res J (Isfahan). 20:1022023. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Lee SH, Do SI, Lee HJ, Kang HJ, Koo BS and Lim YC: Notch1 signaling contributes to stemness in head and neck squamous cell carcinoma. Lab Invest. 96:508–516. 2016.(In Amharic, English). View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Fukusumi T and Califano JA: The NOTCH pathway in head and neck squamous cell carcinoma. J Dent Res. 97:645–653. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333:1154–1157. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Zhang W, Wang J, Huang D, Liu Z, Lu T, Cui C and Li Z: Single-cell sequencing reveals SATB2/NOTCH1 signaling promotes the progression of malignancy of epithelial cells from papillary thyroid cancer. Mol Carcinog. 63:22–33. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Yeh TJ, Luo CW, Du JS, Huang CT, Wang MH, Chuang TM, Gau YC, Cho SF, Liu YC, Hsiao HH, et al: Deciphering the functions of telomerase reverse transcriptase in head and neck cancer. Biomedicines. 11:6912023. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Leão R, Apolónio JD, Lee D, Figueiredo A, Tabori U and Castelo-Branco P: Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: Clinical impacts in cancer. J Biomed Sci. 25:222018. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
Arantes LMRB, Cruvinel-Carloni A, de Carvalho AC, Sorroche BP, Carvalho AL, Scapulatempo-Neto C and Reis RM: TERT Promoter Mutation C228T increases risk for tumor recurrence and death in head and neck cancer patients. Front Oncol. 10:12752020. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Boscolo-Rizzo P, Tirelli G, Polesel J, Sia E, Phillips V, Borsetto D, De Rossi A and Giunco S: TERT promoter mutations in head and neck squamous cell carcinoma: A systematic review and meta-analysis on prevalence and prognostic significance. Oral Oncol. 140:1063982023. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Ganesh MS, Narayanan GS and Kumar R: Change of telomerase activity in peripheral blood of patients with head and neck squamous cell carcinoma pre and post curative treatment. Rep Pract Oncol Radiother. 25:28–34. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Xu Y, Quan Z, Zhan Y, Wang H, Luo J, Wang W and Fan S: SSTR2 positively associates with EGFR and predicts poor prognosis in nasopharyngeal carcinoma. J Clin Pathol. Sep 27–2023.(Epub ahead of print). View Article : Google Scholar
|
|
106
|
Murphrey MB, Quaim L and Varacallo M: Biochemistry, Epidermal Growth Factor Receptor. Disclosure: Lamisa Quaim declares no relevant financial relationships with ineligible companies. Disclosure: Matthew Varacallo declares no relevant financial relationships with ineligible companies. StatPearls; Treasure Island, FL: 2023
|
|
107
|
Zimmermann M, Zouhair A, Azria D and Ozsahin M: The epidermal growth factor receptor (EGFR) in head and neck cancer: its role and treatment implications. Radiat Oncol. 1:112006. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Boccellino M, De Rosa A and Di Domenico M: An ELISA test able to predict the development of oral cancer: The significance of the interplay between steroid receptors and the EGF receptor for early diagnosis. Diagnostics (Basel). 13:20012023. View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Nair S, Bonner JA and Bredel M: EGFR mutations in head and neck squamous cell carcinoma. Int J Mol Sci. 23:38182022. View Article : Google Scholar : PubMed/NCBI
|
|
110
|
Sivarajah S, Kostiuk M, Lindsay C, Puttagunta L, O'Connell DA, Harris J, Seikaly H and Biron VL: EGFR as a biomarker of smoking status and survival in oropharyngeal squamous cell carcinoma. J Otolaryngol Head Neck Surg. 48:12019. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Rehmani HS and Issaeva N: EGFR in head and neck squamous cell carcinoma: Exploring possibilities of novel drug combinations. Ann Transl Med. 8:8132020. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Licitra L, Perrone F, Tamborini E, Bertola L, Ghirelli C, Negri T, Orsenigo M, Filipazzi P, Pastore E, Pompilio M, et al: Role of EGFR family receptors in proliferation of squamous carcinoma cells induced by wound healing fluids of head and neck cancer patients. Ann Oncol. 22:1886–1893. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Numico G, Russi EG, Colantonio I, Lantermo RA, Silvestris N, Vitiello R, Comino A, Abrate M, Zavattero C, Melano A and Merlano M: EGFR status and prognosis of patients with locally advanced head and neck cancer treated with chemoradiotherapy. Anticancer Res. 30:671–676. 2010.PubMed/NCBI
|
|
114
|
Schiff BA, McMurphy AB, Jasser SA, Younes MN, Doan D, Yigitbasi OG, Kim S, Zhou G, Mandal M, Bekele BN, et al: Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer. Clin Cancer Res. 10:8594–8602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Cívico-Ortega JL, González-Ruiz I, Ramos-García P, Cruz-Granados D, Samayoa-Descamps V and González-Moles MÁ: Prognostic and clinicopathological significance of epidermal growth factor receptor (EGFR) expression in oral squamous cell carcinoma: Systematic Review and meta-analysis. Int J Mol Sci. 24:118882023. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Hsu ER, Gillenwater AM, Hasan MQ, Williams MD, El-Naggar AK and Richards-Kortum RR: Real-time detection of epidermal growth factor receptor expression in fresh oral cavity biopsies using a molecular-specific contrast agent. Int J Cancer. 118:3062–3071. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Chen X, Liang R and Zhu X: Anti-EGFR therapies in nasopharyngeal carcinoma. Biomed Pharmacother. 131:1106492020. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 13:9–22. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Bouzoubaa SM, Benlahfid M, Sidqui M, Aboussaouira T, Rifki C, Brouillet S, Traboulsi W, Alfaidy N and Benharouga M: Vascular endothelial growth factor (VEGF) and Endocrine gland-VEGF (EG-VEGF) are down regulated in head and neck cancer. Clin Otolaryngol. 45:788–795. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Schlüter A, Weller P, Kanaan O, Nel I, Heusgen L, Höing B, Haßkamp P, Zander S, Mandapathil M, Dominas N, et al: CD31 and VEGF are prognostic biomarkers in early-stage, but not in late-stage, laryngeal squamous cell carcinoma. BMC Cancer. 18:2722018. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Dumitru CS and Raica M: Vascular endothelial growth factor family and head and neck squamous cell carcinoma. Anticancer Res. 43:4315–4326. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Patel SA, Nilsson MB, Le X, Cascone T, Jain RK and Heymach JV: Molecular mechanisms and future implications of VEGF/VEGFR in cancer therapy. Clin Cancer Res. 29:30–39. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Gisterek I and Kornafel J: Vascular endothelial growth factor in head and neck cancer. Pol Merkur Lekarski. 20:242–244. 2006.(In Polish). PubMed/NCBI
|
|
124
|
Edirisinghe ST, Weerasekera M, De Silva DK, Devmini MT, Pathmaperuma S, Wijesinghe GK, Nisansala T, Maddumage A, Huzaini H, Rich AM, et al: Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR-2) as potential biomarkers for oral squamous cell carcinoma: A Sri Lankan study. Asian Pac J Cancer Prev. 24:267–274. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Zhu H: Squamous cell carcinoma antigen: Clinical application and research status. Diagnostics (Basel). 12:10652022. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yasumatsu R, Nakano T, Hashimoto K, Kogo R, Wakasaki T and Nakagawa T: The clinical value of serum squamous cell carcinoma antigens 1 and 2 in head and neck squamous cell carcinoma. Auris Nasus Larynx. 46:135–140. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
127
|
Schepens EJA, Al-Mamgani A, Karssemakers LHE, van den Broek D, van den Brekel MWM and Lopez-Yurda M: Squamous cell carcinoma antigen in the follow-up of patients with head and neck cancer. Otolaryngol Head Neck Surg. 170:422–430. 2024. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
van Schaik JE, Muller Kobold AC, van der Laan B, van der Vegt B, van Hemel BM and Plaat BEC: Squamous cell carcinoma antigen concentration in fine needle aspiration samples: A new method to detect cervical lymph node metastases of head and neck squamous cell carcinoma. Head Neck. 41:2561–2565. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Souza SP, Serra MGDS, Oliveira NDS, Oliveira MC, Junior JB and Reis TG: Arterial lactate as a predictor of postoperative complications in head and neck squamous cell carcinoma. Braz J Otorhinolaryngol. 88 (Suppl 1):S97–S101. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Blatt S, Voelxen N, Sagheb K, Pabst AM, Walenta S, Schroeder T, Mueller-Klieser W and Ziebart T: Lactate as a predictive marker for tumor recurrence in patients with head and neck squamous cell carcinoma (HNSCC) post radiation: A prospective study over 15 years. Clin Oral Investig. 20:2097–2104. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Brizel DM, Schroeder T, Scher RL, Walenta S, Clough RW, Dewhirst MW and Mueller-Klieser W: Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys. 251:349–353. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Wu M, Li B, Zhang X and Sun G: Serum metabolomics reveals an innovative diagnostic model for salivary gland tumors. Anal Biochem. 655:1148532022. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Srivastava S, Roy R, Gupta V, Tiwari A, Srivastava AN and Sonkar AA: Proton HR-MAS MR spectroscopy of oral squamous cell carcinoma tissues: An ex vivo study to identify malignancy induced metabolic fingerprints. Metabolomics. 7:278–288. 2011. View Article : Google Scholar
|
|
134
|
Kavitha L, Vijayashree Priyadharsini J, Kattula D, Rao UKM, Balaji Srikanth R, Kuzhalmozhi M and Ranganathan K: Expression of CD44 in head and neck squamous cell carcinoma-an in-silico study. Glob Med Genet. 10:221–228. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Gomez KE, Wu F, Keysar SB, Morton JJ, Miller B, Chimed TS, Le PN, Nieto C, Chowdhury FN, Tyagi A, et al: Cancer Cell CD44 mediates macrophage/monocyte-driven regulation of head and neck cancer stem cells. Cancer Res. 80:4185–4198. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Yu SS and Cirillo N: The molecular markers of cancer stem cells in head and neck tumors. J Cell Physiol. 235:65–73. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chen J, Zhou J, Lu J, Xiong H, Shi X and Gong L: Significance of CD44 expression in head and neck cancer: A systemic review and meta-analysis. BMC Cancer. 14:152014. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Xu H, Niu M, Yuan X, Wu K and Liu A: CD44 as a tumor biomarker and therapeutic target. Exp Hematol Oncol. 9:362020. View Article : Google Scholar : PubMed/NCBI
|
|
139
|
Puzzo L, Bianco MR, Salvatorelli L, Tinnirello G, Occhiuzzi F, Latella D and Allegra E: CD44, PDL1, and ATG7 expression in laryngeal squamous cell carcinomas with tissue microarray (TMA) Technique: Evaluation of the potential prognostic and predictive roles. Cancers (Basel). 15:24612023. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Franzmann EJ, Reategui EP, Pedroso F, Pernas FG, Karakullukcu BM, Carraway KL, Hamilton K, Singal R and Goodwin WJ: Soluble CD44 is a potential marker for the early detection of head and neck cancer. Cancer Epidemiol Biomarkers Prev. 16:1348–1355. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Ali F, Siddiqui TA, Sukhia RH, Maqsood A and Ghandhi D: Diagnostic and prognostic role of cancer stem cell biomarkers in oral squamous cell carcinoma; A systematic review. J Pak Med Assoc. 73 (Suppl 1):S32–S39. 2023. View Article : Google Scholar
|
|
142
|
Vasudevan HN and Yom SS: Nasopharyngeal carcinoma and its association with epstein-barr virus. Hematol Oncol Clin North Am. 35:963–971. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
143
|
Jiang W, Chamberlain PD, Garden AS, Kim BY, Ma D, Lo EJ, Bell D, Gunn GB, Fuller CD, Rosenthal DI, et al: Prognostic value of p16 expression in Epstein-Barr virus-positive nasopharyngeal carcinomas. Head Neck. 38 (Suppl 1):E1459–E1466. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Lee LA, Fang TJ, Li HY, Chuang HH, Kang CJ, Chang KP, Liao CT, Chen TC, Huang CG and Yen TC: Effects of Epstein-Barr virus infection on the risk and prognosis of primary laryngeal squamous cell carcinoma: A hospital-based case-control study in Taiwan. Cancers (Basel). 13:17412021. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Wu S, Yuan X, Huang H, Li Y, Cui L, Lin D, Lu W, Feng H, Chen Z, Liu X, et al: Nomogram incorporating Epstein-Barr virus DNA and a novel immune-nutritional marker for survival prediction in nasopharyngeal carcinoma. BMC Cancer. 23:12172023. View Article : Google Scholar : PubMed/NCBI
|
|
146
|
de Lima MAP, Silva ADL, do Nascimento Filho ACS, Cordeiro TL, Bezerra JPS, Rocha MAB, Pinheiro SFL, Pinheiro Junior RFF, Gadelha MDSV and da Silva CGL: Epstein-Barr virus-associated carcinoma of the larynx: A systematic review with meta-analysis. Pathogens. 10:14292021. View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Goldenberg D, Benoit NE, Begum S, Westra WH, Cohen Y, Koch WM, Sidransky D and Califano JA: Epstein-Barr virus in head and neck cancer assessed by quantitative polymerase chain reaction. Laryngoscope. 114:1027–1031. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Javadirad E, Yekta AM, Lorestani RC and Azimivaghar J: A survey of human papillomavirus and epstein-barr virus immunohistochemical status in patients with head and neck squamous cell carcinoma (HNSCC). Head Neck Pathol. 17:325–330. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Wuerdemann N, Joosse S, Klasen C, Prinz J, Demers I, George J, Speel EM, Wagner S and Klußmann JP: ctHPV-DNA based precision oncology for patients with oropharyngeal cancer-Where are we? Laryngorhinootologie. 102:728–734. 2023.(In German). PubMed/NCBI
|
|
150
|
Yan H and Bu P: Non-coding RNA in cancer. Essays Biochem. 65:625–639. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yang QQ and Deng YF: Long non-coding RNAs as novel biomarkers and therapeutic targets in head and neck cancers. Int J Clin Exp Pathol. 7:1286–1292. 2014.PubMed/NCBI
|
|
152
|
Luo X, Qiu Y, Jiang Y, Chen F, Jiang L, Zhou Y, Dan H, Zeng X, Lei YL and Chen Q: Long non-coding RNA implicated in the invasion and metastasis of head and neck cancer: Possible function and mechanisms. Mol Cancer. 17:142018. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Thomaidou AC, Batsaki P, Adamaki M, Goulielmaki M, Baxevanis CN, Zoumpourlis V and Fortis SP: Promising biomarkers in head and neck cancer: The most clinically important miRNAs. Int J Mol Sci. 23:82572022. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Feng H, Zhao F, Luo J, Xu S, Liang Z, Xu W, Bao Y and Qin G: Long non-coding RNA HOTTIP exerts an oncogenic function by regulating HOXA13 in nasopharyngeal carcinoma. Mol Biol Rep. 50:6807–6818. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Fan Y, Yan T, Chai Y, Jiang Y and Zhu X: Long noncoding RNA HOTTIP as an independent prognostic marker in cancer. Clin Chim Acta. 482:224–230. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Jiang H, Zhou L, Shen N, Ning X, Wu D, Jiang K and Huang X: M1 macrophage-derived exosomes and their key molecule lncRNA HOTTIP suppress head and neck squamous cell carcinoma progression by upregulating the TLR5/NF-κB pathway. Cell Death Dis. 13:1832022. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Yin X, Yang W, Xie J, Wei Z, Tang C, Song C, Wang Y, Cai Y, Xu W and Han W: HOTTIP functions as a key candidate biomarker in head and neck squamous cell carcinoma by integrated bioinformatic analysis. Biomed Res Int. 2019:54506172019. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Kozlowska J, Kolenda T, Poter P, Sobocińska J, Guglas K, Stasiak M, Bliźniak R, Teresiak A and Lamperska K: Long intergenic non-coding RNAs in HNSCC: From ‘Junk DNA’ to important prognostic factor. Cancers (Basel). 13:29492021. View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Li Y, Liu Y, Chen G, Liu H, Wu Y, Liu J and Zhang Z: HOTTIP is upregulated in esophageal cancer and triggers the drug resistance. J BUON. 26:1056–1061. 2021.PubMed/NCBI
|
|
160
|
Shen M, Li M and Liu J: Long Noncoding RNA HOTTIP promotes nasopharyngeal cancer cell proliferation, migration, and invasion by inhibiting miR-4301. Med Sci Monit. 25:778–785. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Hussein MA, Valinezhad K, Adel E and Munirathinam G: MALAT-1 is a key regulator of epithelial-mesenchymal transition in cancer: A potential therapeutic target for metastasis. Cancers (Basel). 16:2342024. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Masrour M, Khanmohammadi S, Fallahtafti P and Rezaei N: Long non-coding RNA as a potential diagnostic biomarker in head and neck squamous cell carcinoma: A systematic review and meta-analysis. PLoS One. 18:e02919212023. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Cossu AM, Mosca L, Zappavigna S, Misso G, Bocchetti M, De Micco F, Quagliuolo L, Porcelli M, Caraglia M and Boccellino M: Long Non-coding RNAs as important biomarkers in laryngeal cancer and other head and neck tumours. Int J Mol Sci. 20:34442019. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Han X, Xu Z, Tian G, Tang Z, Gao J, Wei Y and Xu X: Suppression of the long non-coding RNA MALAT-1 impairs the growth and migration of human tongue squamous cell carcinoma SCC4 cells. Arch Med Sci. 15:992–1000. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Kangboonruang K, Wongtrakoongate P, Lertsuwan K, Khachonkham S, Changkaew P, Tangboonduangjit P, Siripoon T, Ngamphaiboon N and Chairoungdua A: MALAT1 decreases the sensitivity of head and neck squamous cell carcinoma cells to radiation and cisplatin. Anticancer Res. 40:2645–2655. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Yao W, Bai Y, Li Y, Guo L, Zeng P, Wang Y, Qi B, Liu S, Qin X, Li Y and Zhao B: Upregulation of MALAT-1 and its association with survival rate and the effect on cell cycle and migration in patients with esophageal squamous cell carcinoma. Tumour Biol. 37:4305–4312. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Liu X, Zhao W and Wang X: Inhibition of long non-coding RNA MALAT1 elevates microRNA-429 to suppress the progression of hypopharyngeal squamous cell carcinoma by reducing ZEB1. Life Sci. 262:1184802020. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Duan Y, Yue K, Ye B, Chen P, Zhang J, He Q, Wu Y, Lai Q, Li H, Wu Y, et al: LncRNA MALAT1 promotes growth and metastasis of head and neck squamous cell carcinoma by repressing VHL through a non-canonical function of EZH2. Cell Death Dis. 14:1492023. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Ghafouri-Fard S, Dashti S, Farsi M and Taheri M: HOX transcript antisense RNA: An oncogenic lncRNA in diverse malignancies. Exp Mol Pathol. 118:1045782021. View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Xiang Y and Hua Q: The role and mechanism of long non-coding RNA HOTAIR in the oncogenesis, diagnosis, and treatment of head and neck squamous cell carcinoma. Clin Med Insights Oncol. 17:117955492311690992023. View Article : Google Scholar : PubMed/NCBI
|
|
171
|
Shi L, Zhang D, Han H, Zhang L, Li S, Yang F and He C: HOTAIR knockdown impairs metastasis of cervical cancer cells by down-regulating metastasis-related genes. J Obstet Gynaecol. 43:21810602023. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Hu D and Messadi DV: Immune-Related long non-coding RNA signatures for tongue squamous cell carcinoma. Curr Oncol. 30:4817–4832. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Yuan X, Shen Q and Ma W: Long Noncoding RNA Hotair promotes the progression and immune escape in laryngeal squamous cell carcinoma through MicroRNA-30a/GRP78/PD-L1 Axis. J Immunol Res. 2022:51414262022. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Yang G, Huang T, Wu Y, Wang J, Pan Z, Chen Y, Pan F and Wang Y: Clinicopathological and prognostic significance of the long non-coding RNA HOTAIR high expression in head and neck squamous cell carcinoma: A systematic review and meta-analysis. Transl Cancer Res. 11:2536–2552. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Li F and Hu CP: Long Non-Coding RNA urothelial carcinoma associated 1 (UCA1): Insight into Its role in human diseases. Crit Rev Eukaryot Gene Expr. 25:191–197. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Wang X, Sun M, Gao Z, Yin L, Pu Y, Zhu Y, Wang X and Liu R: N-nitrosamines-mediated downregulation of LncRNA-UCA1 induces carcinogenesis of esophageal squamous by regulating the alternative splicing of FGFR2. Sci Total Environ. 855:1589182023. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Sun S, Gong C and Yuan K: LncRNA UCA1 promotes cell proliferation, invasion and migration of laryngeal squamous cell carcinoma cells by activating Wnt/β-catenin signaling pathway. Exp Ther Med. 17:1182–1189. 2019.PubMed/NCBI
|
|
178
|
Huang HH, You GR, Tang SJ, Chang JT and Cheng AJ: Molecular signature of long non-coding RNA associated with areca nut-induced head and neck cancer. Cells. 12:8732023. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Qian Y, Liu D, Cao S, Tao Y, Wei D, Li W, Li G, Pan X and Lei D: Upregulation of the long noncoding RNA UCA1 affects the proliferation, invasion, and survival of hypopharyngeal carcinoma. Mol Cancer. 16:682017. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Liu C, Jin J, Shi J, Wang L, Gao Z, Guo T and He Y: Long noncoding RNA UCA1 as a novel biomarker of lymph node metastasis and prognosis in human cancer: A meta-analysis. Biosci Rep. 39:BSR201809952019. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Zhang C, Xie L, Fu Y, Yang J and Cui Y: lncRNA MIAT promotes esophageal squamous cell carcinoma progression by regulating miR-1301-3p/INCENP axis and interacting with SOX2. J Cell Physiol. 235:7933–7944. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Da CM, Gong CY, Nan W, Zhou KS, Wu ZL and Zhang HH: The role of long non-coding RNA MIAT in cancers. Biomed Pharmacother. 129:1103592020. View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Song F, Yang Y and Liu J: Long non-coding RNA MIAT promotes the proliferation and invasion of laryngeal squamous cell carcinoma cells by sponging microRNA-613. Exp Ther Med. 21:2322021. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Liu W, Wang Z, Wang C and Ai Z: Long non-coding RNA MIAT promotes papillary thyroid cancer progression through upregulating LASP1. Cancer Cell Int. 19:1942019. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Zhong W, Xu Z, Wen S, Xie T, Wang F, Wang Q and Chen J: Long non-coding RNA myocardial infarction associated transcript promotes epithelial-mesenchymal transition and is an independent risk factor for poor prognosis of tongue squamous cell carcinoma. J Oral Pathol Med. 48:720–727. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Wang R, Zhao L, Ji L, Bai L and Wen Q: Myocardial infarction associated transcript (MIAT) promotes papillary thyroid cancer progression via sponging miR-212. Biomed Pharmacother. 118:1092982019. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Guo K, Qian K, Shi Y, Sun T and Wang Z: LncRNA-MIAT promotes thyroid cancer progression and function as ceRNA to target EZH2 by sponging miR-150-5p. Cell Death Dis. 12:10972021. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Dey Ghosh R and Guha Majumder S: Circulating long non-coding RNAs could be the potential prognostic biomarker for liquid biopsy for the clinical management of oral squamous cell carcinoma. Cancers (Basel). 14:55902022. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Wang H, Zhou Z, Lin W, Qian Y, He S and Wang J: MicroRNA-21 promotes head and neck squamous cell carcinoma (HNSCC) induced transition of bone marrow mesenchymal stem cells to cancer-associated fibroblasts. BMC Cancer. 23:11352023. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Doukas SG, Vageli DP, Lazopoulos G, Spandidos DA, Sasaki CT and Tsatsakis A: The Effect of NNK, A tobacco smoke carcinogen, on the miRNA and Mismatch DNA repair expression profiles in lung and head and neck squamous cancer cells. Cells. 9:10312020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Shah S, Jadhav K, Shah V, Gupta N and Dagrus K: miRNA 21: Diagnostic prognostic and therapeutic marker for oral cancer. Microrna. 5:175–179. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Arantes LM, Laus AC, Melendez ME, de Carvalho AC, Sorroche BP, De Marchi PR, Evangelista AF, Scapulatempo-Neto C, de Souza Viana L and Carvalho AL: MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol. Oncotarget. 8:9911–9921. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Ishinaga H, Okugawa Y, Hou B, He F, Yin C, Murata M, Toiyama Y and Takeuchi K: The role of miR-21 as a predictive biomarker and a potential target to improve the effects of chemoradiotherapy against head and neck squamous cell carcinoma. J Radiat Res. 64:668–676. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Vageli DP, Doukas PG, Shah R, Boyi T, Liu C and Judson BL: A novel saliva and serum miRNA panel as a potential useful index for oral cancer and the association of miR-21 with smoking history: A pilot study. Cancer Prev Res (Phila). 16:653–659. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
195
|
Irimie-Aghiorghiesei AI, Pop-Bica C, Pintea S, Braicu C, Cojocneanu R, Zimța AA, Gulei D, Slabý O and Berindan-Neagoe I: Prognostic Value of MiR-21: An updated meta-analysis in head and neck squamous cell carcinoma (HNSCC). J Clin Med. 8:20412019. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Sheng S, Su W, Mao D, Li C, Hu X, Deng W, Yao Y and Ji Y: MicroRNA-21 induces cisplatin resistance in head and neck squamous cell carcinoma. PLoS One. 17:e02670172022. View Article : Google Scholar : PubMed/NCBI
|
|
197
|
Kabzinski J, Maczynska M and Majsterek I: MicroRNA as a novel biomarker in the diagnosis of head and neck cancer. Biomolecules. 11:8442021. View Article : Google Scholar : PubMed/NCBI
|
|
198
|
Luo C, Zhang J, Zhang Y, Zhang X, Chen Y and Fan W: Low expression of miR-let-7a promotes cell growth and invasion through the regulation of c-Myc in oral squamous cell carcinoma. Cell Cycle. 19:1983–1993. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
199
|
Ulusan M, Sen S, Yilmazer R, Dalay N and Demokan S: The let-7 microRNA binding site variant in KRAS as a predictive biomarker for head and neck cancer patients with lymph node metastasis. Pathol Res Pract. 239:1541472022. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Lee YS and Dutta A: The tumor suppressor microRNA let-7 represses the HMGA2 oncogene. Genes Dev. 21:1025–1030. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
201
|
Yu D, Liu X, Han G, Liu Y, Zhao X, Wang D, Bian X, Gu T and Wen L: The let-7 family of microRNAs suppresses immune evasion in head and neck squamous cell carcinoma by promoting PD-L1 degradation. Cell Commun Signal. 17:1732019. View Article : Google Scholar : PubMed/NCBI
|
|
202
|
Chirshev E, Oberg KC, Ioffe YJ and Unternaehrer JJ: Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin Transl Med. 8:242019. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Kinoshita T, Hanazawa T, Nohata N, Okamoto Y and Seki N: The functional significance of microRNA-375 in human squamous cell carcinoma: Aberrant expression and effects on cancer pathways. J Hum Genet. 57:556–563. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
204
|
Mazumder S, Datta S, Ray JG, Chaudhuri K and Chatterjee R: Liquid biopsy: miRNA as a potential biomarker in oral cancer. Cancer Epidemiol. 58:137–145. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Chen J, Cai Z, Hu J, Zhou L, Zhang P and Xu X: MicroRNA-375 in extracellular vesicles-novel marker for esophageal cancer diagnosis. Medicine (Baltimore). 102:e328262023. View Article : Google Scholar : PubMed/NCBI
|
|
206
|
Huni KC, Cheung J, Sullivan M, Robison WT, Howard KM and Kingsley K: Chemotherapeutic drug resistance associated with differential miRNA expression of miR-375 and miR-27 among oral cancer cell lines. Int J Mol Sci. 24:12442023. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Gazdzicka J, Golabek K, Strzelczyk JK and Ostrowska Z: Epigenetic modifications in head and neck cancer. Biochem Genet. 58:213–244. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Castilho RM, Squarize CH and Almeida LO: Epigenetic modifications and head and neck cancer: Implications for tumor progression and resistance to therapy. Int J Mol Sci. 18:15062017. View Article : Google Scholar : PubMed/NCBI
|
|
209
|
Li J, Huang Q, Zeng F, Li W, He Z, Chen W, Zhu W and Zhang B: The prognostic value of global DNA hypomethylation in cancer: A meta-analysis. PLoS One. 9:e1062902014. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Temilola DO, Adeola HA, Grobbelaar J and Chetty M: Liquid biopsy in head and neck cancer: Its present state and future role in Africa. Cells. 12:26632023. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Liu HE, Triboulet M, Zia A, Vuppalapaty M, Kidess-Sigal E, Coller J, Natu VS, Shokoohi V, Che J, Renier C, et al: Workflow optimization of whole genome amplification and targeted panel sequencing for CTC mutation detection. NPJ Genom Med. 2:342017. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Kong L and Birkeland AC: Liquid biopsies in head and neck cancer: Current state and future challenges. Cancers (Basel). 13:18742021. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Huang X, Duijf PHG, Sriram S, Perera G, Vasani S, Kenny L, Leo P and Punyadeera C: Circulating tumour DNA alterations: emerging biomarker in head and neck squamous cell carcinoma. J Biomed Sci. 30:652023. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Thierry AR, El Messaoudi S, Gahan PB, Anker P and Stroun M: Origins, structures, and functions of circulating DNA in oncology. Cancer Metastasis Rev. 35:347–376. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Silvoniemi A, Laine J, Aro K, Nissi L, Bäck L, Schildt J, Hirvonen J, Hagström J, Irjala H, Aaltonen LM, et al: Circulating tumor DNA in head and neck squamous cell carcinoma: Association with metabolic tumor burden determined with FDG-PET/CT. Cancers (Basel). 15:39702023. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Allevato MM, Smith JD, Brenner MJ and Chinn SB: Tumor-Derived exosomes and the role of liquid biopsy in human papillomavirus oropharyngeal squamous cell carcinoma. Cancer J. 29:230–237. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, Zheng Y, Hoshino A, Brazier H, Xiang J, et al: Double-stranded DNA in exosomes: A novel biomarker in cancer detection. Cell Res. 24:766–769. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Li S, Yi M, Dong B, Tan X, Luo S and Wu K: The role of exosomes in liquid biopsy for cancer diagnosis and prognosis prediction. Int J Cancer. 148:2640–2651. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Kabzinski J, Kucharska-Lusina A and Majsterek I: RNA-Based liquid biopsy in head and neck cancer. Cells. 12:19162023. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Lu YC, Chang JT, Huang YC, Huang CC, Chen WH, Lee LY, Huang BS, Chen YJ, Li HF and Cheng AJ: Combined determination of circulating miR-196a and miR-196b levels produces high sensitivity and specificity for early detection of oral cancer. Clin Biochem. 48:115–121. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Kumar P, Gupta S and Das BC: Saliva as a potential non-invasive liquid biopsy for early and easy diagnosis/prognosis of head and neck cancer. Transl Oncol. 40:1018272024. View Article : Google Scholar : PubMed/NCBI
|
|
223
|
Mishra V, Singh A, Chen X, Rosenberg AJ, Pearson AT, Zhavoronkov A, Savage PA, Lingen MW, Agrawal N and Izumchenko E: Application of liquid biopsy as multi-functional biomarkers in head and neck cancer. Br J Cancer. 126:361–370. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Wang X and Li BB: Deep learning in head and neck tumor multiomics diagnosis and analysis: Review of the literature. Front Genet. 12:6248202021. View Article : Google Scholar : PubMed/NCBI
|
|
225
|
Haider M, Jagal J, Bajbouj K, Sharaf BM, Sahnoon L, Okendo J, Semreen MH, Hamda M and Soares NC: Integrated multi-omics analysis reveals unique signatures of paclitaxel-loaded poly(lactide-co-glycolide) nanoparticles treatment of head and neck cancer cells. Proteomics. 23:e22003802023. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Eichberger J, Froschhammer D, Schulz D, Scholz KJ, Federlin M, Ebensberger H, Reichert TE, Ettl T and Bauer RJ: BMSC-HNC Interaction: Exploring effects on bone integrity and head and neck cancer progression. Int J Mol Sci. 24:144172023. View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Borkowska EM, Barańska M, Kowalczyk M and Pietruszewska W: Detection of PIK3CA gene mutation in head and neck squamous cell carcinoma using droplet digital PCR and RT-qPCR. Biomolecules. 11:8182021. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
Khedkar HN, Chen LC, Kuo YC, Wu ATH and Huang HS: Multi-Omics identification of genetic alterations in head and neck squamous cell carcinoma and therapeutic efficacy of HNC018 as a novel multi-target agent for c-MET/STAT3/AKT signaling axis. Int J Mol Sci. 24:102472023. View Article : Google Scholar : PubMed/NCBI
|
|
229
|
Ehrlich M: DNA hypomethylation in cancer cells. Epigenomics. 1:239–259. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Guo Z, Liu W, Yang Y, Zhang S, Li C and Yang W: DNA methylation in the genesis, progress and prognosis of head and neck cancer. Holist Integ Oncol. 2:232023. View Article : Google Scholar
|
|
231
|
Capkova M, Sachova J, Strnad H, Kolář M, Hroudová M, Chovanec M, Čada Z, Šteffl M, Valach J, Kastner J, et al: Microarray analysis of serum mRNA in patients with head and neck squamous cell carcinoma at whole-genome scale. Biomed Res Int. 2014:4086832014. View Article : Google Scholar : PubMed/NCBI
|
|
232
|
Li Y, Porta-Pardo E, Tokheim C, Bailey MH, Yaron TM, Stathias V, Geffen Y, Imbach KJ, Cao S, Anand S, et al: Pan-cancer proteogenomics connects oncogenic drivers to functional states. Cell. 186:3921–3944.e25. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Assarsson E, Lundberg M, Holmquist G, Björkesten J, Thorsen SB, Ekman D, Eriksson A, Rennel Dickens E, Ohlsson S, Edfeldt G, et al: Homogenous 96-plex PEA immunoassay exhibiting high sensitivity, specificity, and excellent scalability. PLoS One. 9:e951922014. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Pawlicka M, Gumbarewicz E, Blaszczak E and Stepulak A: Transcription factors and markers related to epithelial-mesenchymal transition and their role in resistance to therapies in head and neck cancers. Cancers (Basel). 16:13542024. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Fornieles G, Núñez MI and Expósito J: Matrix metalloproteinases and their inhibitors as potential prognostic biomarkers in head and neck cancer after radiotherapy. Int J Mol Sci. 25:5272023. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Liao C, An J, Tan Z, Xu F, Liu J and Wang Q: Changes in protein glycosylation in head and neck squamous cell carcinoma. J Cancer. 12:1455–1466. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Zhao X, Liu X and Cui L: Development of a five-protein signature for predicting the prognosis of head and neck squamous cell carcinoma. Aging (Albany NY). 12:19740–19755. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
238
|
Yang T, Hui R, Nouws J, Sauler M, Zeng T and Wu Q: Untargeted metabolomics analysis of esophageal squamous cell cancer progression. J Transl Med. 20:1272022. View Article : Google Scholar : PubMed/NCBI
|
|
239
|
Wu Z, Han Y, Wan Y, Hua X, Chill SS, Teshome K, Zhou W, Liu J, Wu D, Hutchinson A, et al: Oral microbiome and risk of incident head and neck cancer: A nested case-control study. Oral Oncol. 137:1063052023. View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Stasiewicz M and Karpinski TM: The oral microbiota and its role in carcinogenesis. Semin Cancer Biol. 86:633–642. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Dorobisz K, Dorobisz T and Zatonski T: The Microbiome's influence on head and neck cancers. Curr Oncol Rep. 25:163–171. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Benjamin WJ, Wang K, Zarins K, Bellile E, Blostein F, Argirion I, Taylor JMG, D'Silva NJ, Chinn SB, Rifkin S, et al: Oral microbiome community composition in head and neck squamous cell carcinoma. Cancers (Basel). 15:25492023. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Kunhabdulla H, Manas R, Shettihalli AK, Reddy CRM, Mustak MS, Jetti R, Abdulla R, Sirigiri DR, Ramdan D and Ammarullah MI: Identifying biomarkers and therapeutic targets by multiomic analysis for HNSCC: Precision medicine and healthcare management. ACS Omega. 9:12602–12610. 2024.PubMed/NCBI
|
|
244
|
Xiao M, Zhang X, Zhang D, Deng S, Zheng A, Du F, Shen J, Yue L, Yi T, Xiao Z and Zhao Y: Complex interaction and heterogeneity among cancer stem cells in head and neck squamous cell carcinoma revealed by single-cell sequencing. Front Immunol. 13:10509512022. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Li M, Sun D, Song N, Chen X, Zhang X, Zheng W, Yu Y and Han C: Mutant p53 in head and neck squamous cell carcinoma: Molecular mechanism of gain-of-function and targeting therapy (Review). Oncol Rep. 50:1622023. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Snietura M, Jaworska M, Mlynarczyk-Liszka J, Goraj-Zajac A, Piglowski W, Lange D, Wozniak G, Nowara E and Suwinski R: PTEN as a prognostic and predictive marker in postoperative radiotherapy for squamous cell cancer of the head and neck. PLoS One. 7:e333962012. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Bossi P, Resteghini C, Paielli N, Licitra L, Pilotti S and Perrone F: Prognostic and predictive value of EGFR in head and neck squamous cell carcinoma. Oncotarget. 7:74362–74379. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
248
|
Qiao XW, Jiang J, Pang X, Huang MC, Tang YJ, Liang XH and Tang YL: The Evolving Landscape of PD-1/PD-L1 pathway in head and neck cancer. Front Immunol. 11:17212020. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Edirisinghe S, Weerasekera M, De Silva D, Devmini MT, Pathmaperuma S, Wijesinghe GK, Nisansala T, Maddumage A, Huzaini H, Rich AM, et al: Vascular endothelial growth factor A (VEGF-A) and vascular endothelial growth factor receptor 2 (VEGFR-2) as potential biomarkers for oral squamous cell carcinoma: A Sri Lankan study. Asian Pac J Cancer Prev. 24:267–274. 2023. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Augustin JG, Lepine C, Morini A, Brunet A, Veyer D, Brochard C, Mirghani H, Péré H and Badoual C: HPV detection in head and neck squamous cell carcinomas: What is the issue? Front Oncol. 10:17512020. View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Tan D, Wu Y, Hu L, He P, Xiong G, Bai Y and Yang K: Long noncoding RNA H19 is up-regulated in esophageal squamous cell carcinoma and promotes cell proliferation and metastasis. Dis Esophagus. 30:1–9. 2017.
|
|
252
|
Yoshizaki T, Kondo S, Dochi H, Kobayashi E, Mizokami H, Komura S and Endo K: Recent advances in assessing the clinical implications of epstein-barr virus infection and their application to the diagnosis and treatment of nasopharyngeal carcinoma. Microorganisms. 12:142023. View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Ye D, Deng Y and Shen Z: The role and mechanism of MALAT1 Long Non-Coding RNA in the diagnosis and treatment of head and neck squamous cell carcinoma. Onco Targets Ther. 14:4127–4136. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
254
|
Cantile M, Di Bonito M, Tracey De Bellis M and Botti G: Functional Interaction among lncRNA HOTAIR and MicroRNAs in cancer and other human diseases. Cancers (Basel). 13:5702021. View Article : Google Scholar : PubMed/NCBI
|
|
255
|
Wang Y, Wang S, Ren Y and Zhou X: The Role of lncRNA Crosstalk in leading cancer metastasis of head and neck squamous cell carcinoma. Front Oncol. 10:5618332020. View Article : Google Scholar : PubMed/NCBI
|
|
256
|
Mohammadi C, Gholamzadeh Khoei S, Fayazi N, Mohammadi Y and Najafi R: miRNA as promising theragnostic biomarkers for predicting radioresistance in cancer: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 157:1031832021. View Article : Google Scholar : PubMed/NCBI
|
|
257
|
Ma Y, Shen N, Wicha MS and Luo M: The Roles of the Let-7 Family of MicroRNAs in the regulation of cancer stemness. Cells. 10:24152021. View Article : Google Scholar : PubMed/NCBI
|
